MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FULLER, R. W.
Right arrow Articles by BROMER, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FULLER, R. W.
Right arrow Articles by BROMER, W. W.

Molecular Pharmacology, Vol 8, 345-352, Copyright © 1972 by the American Society for Pharmacology and Experimental Therapeutics

Increase of Hepatic L-Phenylalanine: Pyruvate Aminotransferase by Glucagon in Rats

Possible Role of Adenosine Cyclic 3',5'-Monophosphate as a Mediator

RAY W. FULLER 1, HAROLD D. SNODDY 1, and WILLIAM W. BROMER 1

1 Division of Biochemical and Physiological Research, The Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46206

Glucagon caused an approximately 4-fold increase in hepatic L-phenylalanine: pyruvate aminotransferase activity in rats 24 hr after subcutaneous injection: Tetraiodo, mononitro, and monodeamido derivatives of glucagon also increased enzyme activity, the tetraiodoglucagon being more active than glucagon itself. Theophylline, an inhibitor of cyclic AMP phosphodiesterase, enhanced the action of glucagon in increasing phenylalanine aminotransferase. Higher doses of theophylline and of epinephrine, which, like glucagon, can stimulate adenyl cyclase, also increased the activity of this enzyme in both intact and adrenalectomized rats. N6, O2-Dibutyryl cyclic AMP likewise increased the enzyme, and theophylline greatly potentiated its action. The results are consistent with a role for cyclic AMP as a mediator in the elevation of hepatic phenylalanine aminotransferase. This enzyme was shown to be distinct from alanine aminotransferase, in that the former enzyme could be elevated by glucagon or dibutyryl cyclic AMP or particularly inactivated by freezing, independently of alanine aminotransferase, whereas alanine aminotransferase could be elevated by deprivation of food or inhibited by p-chloromercuribenzoate independently of phenylalanine aminotransferase. Liver extracts catalyzed the transamination of phenylalanine with either pyruvate or 2-oxoglutarate as the amino acceptor, but only the phenylanine:pyruvate transamination was increased by prior 24-hr treatment with glucagon. Phenylalanine aminotransferase activity in heart and kidney was as high as in the liver; brain had lower activity. Glucagon did not affect the enzyme in tissues other than the liver.

Submitted on December 14, 1971







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1972 by the American Society for Pharmacology and Experimental Therapeutics